Resources

Four places to go deeper than this lesson, or to check a citation yourself before it goes into a real Lakeshore document. All four were checked and loading at the time this page was written.

• 21 CFR Part 7, Subpart A, Section 7.3, Cornell Legal Information Institute — the full definitions section this lesson quotes from: recall, market withdrawal, stock recovery, and the Class I/II/III recall classification, all in one place. Worth reading in full once to see how tightly FDA defines each term.

• 21 CFR Part 7, Subpart C, Section 7.41, eCFR — the six-factor health hazard evaluation this lesson walks against Lakeshore’s plasma lot. eCFR’s “current as of” banner is useful for confirming you’re reading the in-force version, not an amended-out one.

• FDA, “CDER GCP Inspections and Outcomes” (PDF) — the same presentation module 1 used for the NAI/VAI/OAI slide, reused here for its Warning Letter slide (17). Read it with the same scope caveat: this is a presentation about Good Clinical Practice (GCP) inspections of clinical drug trials, not about CGMP inspections of a manufacturing or blood-collection facility. Only the Warning Letter’s general character — public, redacted, informal and advisory — transfers; the clinical-trial content around it does not.

• FDA, Recalls, Market Withdrawals, & Safety Alerts — FDA’s own public landing page for actual, real recall notices across every product type it regulates. Useful for seeing what a real recall classification and public notice actually look like in practice, without treating any single listed recall as a stand-in for Lakeshore’s fictional scenario.